BLUE MEDUSA, the new band led by former ARCH ENEMY and THE AGONIST vocalist Alissa White-Gluz, has released its third single, ...

The FDA’s recent inclusion of certain GLP-1 receptor agonists on a so-called “Green List” is often portrayed as a regulatory ...

Ren and Chris Webby's Asylum jumps from reggae to soul to drum and bass, runs on weed and pharmaceuticals, and somehow comes ...

Atypical anorexia presents without low body weight, leading clinicians to frequently overlook the disorder and miss critical ...

What does metabolic health mean, and how do you improve it? Experts chime in on some easy ways to get your body into a better ...

Blue Medusa, the new band fronted by former Arch Enemy and The Agonist vocalist Alissa White-Gluz, has dropped its third single, “Crocodile.” Dark, tense and quietly menacing, “Crocodile.” digs into ...

Rhythm Pharmaceuticals stock has eased after a multimillion-dollar insider sale, yet the latest Q2 2026 figures show double-digit revenue growth and a still sizable market capitalization.

The Protein Boom Is Everywhere. For Our Patients, It Was Always Urgent / cancer, Cancer Nutrition, OncoDaily, Oncology, ...

As Takeda’s oveporexton (Orzeyful) becomes a first-in-class treatment for narcolepsy type 1, industry eyes broader indications for orexin receptor agonists. The FDA has approved Takeda’s oveporexton ...

FDA approval positions oral selective OX2R agonism as a first-in-class approach intended to restore orexin signaling and mitigate wake–REM instability underlying narcolepsy type 1 with cataplexy.

Experts explain the real risk.